MK-5046

• Description :

  MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity[1][2][3].

• UNSPSC :

  12352005

• Target :

  Bombesin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/MK-5046.html

• Concentration :

  10mM

• Purity :

  99.75

• Solubility :

  DMSO : 14.29 mg/mL (ultrasonic)

• Smiles :

  O[C@](CC1=NC(CC2(C(F)(F)F)CC2)=CN1)(C(F)(F)F)C3=CC=C(N4C=CC=N4)C=C3

• Molecular Formula :

  C20H18F6N4O

• Molecular Weight :

  444.37

• References & Citations :

  [1]Guan XM, et al. Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist. J Pharmacol Exp Ther. 2011 Feb;336 (2) :356-364.|[2]Sebhat IK, et al. Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity. ACS Med Chem Lett. 2010 Oct 18;2 (1) :43-47.|[3]Ramos-Alvarez I, et al. The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3. J Pharmacol Exp Ther. 2022 Aug;382 (2) :66-78.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1022152-70-0]